Novartis Venture Fund

Apr 02, 2019

Selumetinib gets the U.S. Breakthrough Therapy Designation Selumetinib- an investigational drug, for the treatment of pediatric patients aged three years and above suffering from symptomatic and/or progressive, inoperable neurofibromatosis type 1 (NF1), plexiform neurofibromas (PN)- a rare genetic condition, has...

Sep 20, 2018

Epic Sciences garners USD 52 Million for blood tests in cancer patients Epic Sciences received USD 52 million to progress its suite of liquid biopsies that utilizes computer vision and machine learning to find circulating tumour cells while characterizing the immune response of the body at the same time. The Cancer...